MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
Why HCWB Stock dropped -3.28% Today — RQD Quant Desk Flash
$1.18 -3.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.17
HCW Biologics Inc. (HCWB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HCWB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HCWB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, HCW Biologics Inc. (NASDAQ: HCWB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.18 (-3.28% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HCWB ranks #982 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HCWB compare to PRFX and SBFM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCWB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 20.0%, and ROIC of -35.0%. By comparison, PRFX (PRF Technologies Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, HCWB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HCWB?
▼
Per HCWB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001828673), HCW Biologics Inc. generated $54.2K in revenue (-97.9% YoY), -$8.0M in net income, and -$13.4M in free cash flow against $24.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.17 (-0.78%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCWB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY HCWB SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (30% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.3 (OVERSOLD (<32))
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.60-22.5% Next Q
35
Q2 (-2Q)Grade E$1.24-5.6% Next Q
32
Q3 (-1Q)Grade E$1.17+0.9% Next Q
30
CurrentGrade E$1.18-10.3% Hist 90D α
27
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HCWB Turnaround Squeeze
While HCWB currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.92) and Max Pain ($1.24) forces dealer call-delta covering toward $25.14.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCWB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HCWB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HCWB Stock dropped -3.28% Today — RQD Quant Desk Flash
HCW Biologics Inc. (HCWB) dropped -3.28% to $1.18, trading at 2% of its 52-week range ($1.09 – $23.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.09 – $23.94) with RSI-14 at 31.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.18 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 1.1% gross margin and $0 annual free cash flow.
Live HCWB Headlines & Catalysts
MARKET WIREReuters • 4h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 6h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 10h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCWB)
- ✓Walkthrough of HCWB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HCWB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.30%⚡ TESTING RESISTANCE
2026-10-30O $1.16H $1.19L $1.10C $1.18VOL 34.5K
RES: $2.33SUP: $0.98SMA50: $1.92SMA200: $4.12
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HCWB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HCWB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HCWB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HCWB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCWB)
Health Care Rank #982 of 1016
⚔️ PRFX vs HCWB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HCWB vs. PRFX, SBFM, APVO, SILO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, HCW Biologics Inc. (HCWB) ranks #982 by composite RQD confidence (27/100, grade E) and #983 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, HCWB leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with HCWB at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HCWB
ACTIVE
HCW Biologics Inc. | E | 27/100 | — | 20.0% | -35.0% | -3.28% | $2.6M | Benchmark Subject |
| PRFX PRF Technologies Ltd. | D- | 39/100 | — | -30.0% | -35.0% | -3.86% | $2.6M | /prfx-vs-hcwb → |
| SBFM Sunshine Biopharma Inc. | D | 44/100 | — | 33.8% | -21.4% | +7.07% | $2.5M | /sbfm-vs-hcwb → |
| APVO Aptevo Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +4.62% | $2.5M | /apvo-vs-hcwb → |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-hcwb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001828673In its most recent audited fiscal period (FY2025, filed 2025-12-31), HCW Biologics Inc. (HCWB) reported GAAP revenue of $54.2K (-97.9% vs. FY2024 revenue of $2.6M ) , GAAP net income of -$8.0M, operating cash flow of -$13.4M, and free cash flow of -$13.4M (+7.6% YoY). On the balance sheet, HCWB closed FY2025 with $24.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $54.2K | -$8.0M | -$13.4M | -$13.4M | $24.5M | — |
| FY2024 (FY) | 2024-12-31 | $2.6M | -$30.0M | -$14.2M | -$14.5M | $30.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$25.0M | -$22.5M | -$22.5M | — | — |
3. HCWB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HCWB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, HCW Biologics Inc. (NASDAQ: HCWB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.18 (-3.28% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HCWB ranks #982 in composite RQD confidence.
How does HCWB compare to PRFX and SBFM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCWB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 20.0%, and ROIC of -35.0%. By comparison, PRFX (PRF Technologies Ltd.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and SBFM (Sunshine Biopharma Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.4%, cap $2.5M). Among the 5-stock peer group, HCWB leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HCWB?
Per HCWB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001828673), HCW Biologics Inc. generated $54.2K in revenue (-97.9% YoY), -$8.0M in net income, and -$13.4M in free cash flow against $24.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HCWB trading relative to its 50-day, 200-day, and 52-week technical levels?
HCWB last traded at $1.18 (-3.28% on volume of 33,448 shares), positioning the stock -38.54% below its 50-day simple moving average ($1.92) and -71.36% below its 200-day simple moving average ($4.12). Across its 52-week range of $1.09 to $23.94, HCWB sits at the 0.4% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.03 to $1.33).
HCWB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HCWB stock moving today?
Why HCWB Stock dropped -3.28% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.